Literature DB >> 15343065

Blockade of D2 dopamine receptors in the VTA induces a long-lasting enhancement of the locomotor activating effects of amphetamine.

L M Tanabe1, N Suto, E Creekmore, C L Steinmiller, P Vezina.   

Abstract

The present study examined the effects of pre-exposure to eticlopride, a D2 dopamine receptor antagonist, in the ventral tegmental area (VTA) on the subsequent locomotor activating effects of amphetamine (AMPH). Rats were pre-exposed to one of three doses of eticlopride (0.75, 3.0 or 12.0 microg/0.5 microl per side) or saline (0.5 microl/side) in the VTA, once every third day, for a total of three infusions. Locomotor activity was recorded for 2 h following each pre-exposure injection. The low and intermediate doses of eticlopride produced no effects, while the high dose decreased locomotor activity compared to saline controls. 10-14 days following the last pre-exposure injection, all rats were challenged with AMPH (1.0 mg/kg, ip) and locomotor activity was recorded. Rats pre-exposed to the low dose of eticlopride exhibited enhanced locomotor activity whereas those pre-exposed to the intermediate or high doses did not differ from saline pre-exposed controls, suggesting that blockade of D2 dopamine receptors in the VTA can lead to sensitized locomotor responding to AMPH. To investigate the possible mechanism by which the low dose of eticlopride induced sensitization, extracellular levels of dopamine were measured as increasing concentrations of eticlopride (0.1, 1.0, 10.0 and 100.0 micromol/l) were perfused through a microdialysis probe implanted in the VTA. Only the lowest eticlopride concentration elevated extracellular dopamine levels. Therefore, as in the case of AMPH-induced sensitization, the induction by eticlopride of sensitization to AMPH may be initiated by the ability of eticlopride to increase extracellular levels of dopamine in the VTA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343065     DOI: 10.1097/00008877-200409000-00013

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

1.  Acute withdrawal-related hypophagia elicited by amphetamine is attenuated by pretreatment with selective dopamine D1 or D2 receptor antagonists in rats.

Authors:  Wesley White; Jason D Beyer; Ilsun M White
Journal:  Physiol Behav       Date:  2015-08-07

2.  Effects of amphetamine exposure during adolescence on behavior and prelimbic cortex neuron activity in adulthood.

Authors:  Luke K Sherrill; Joshua M Gulley
Journal:  Brain Res       Date:  2018-05-21       Impact factor: 3.252

Review 3.  Drug wanting: behavioral sensitization and relapse to drug-seeking behavior.

Authors:  Jeffery D Steketee; Peter W Kalivas
Journal:  Pharmacol Rev       Date:  2011-04-13       Impact factor: 25.468

4.  Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.

Authors:  Joshua D Gross; Shane W Kaski; Adam B Schroer; Kimberley A Wix; David P Siderovski; Vincent Setola
Journal:  J Psychopharmacol       Date:  2018-01-24       Impact factor: 4.153

5.  Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice.

Authors:  M A Kelly; M J Low; M Rubinstein; T J Phillips
Journal:  Genes Brain Behav       Date:  2008-07       Impact factor: 3.449

6.  An Assessment between D1 Receptor Agonist and D2 receptor Antagonist into the Ventral Tegmental Area on Conditioned Place Preference and Locomotor Activity.

Authors:  Seyed Mostafa Ahmadian; Hojjatallah Alaei; Parisa Ghahremani
Journal:  Adv Biomed Res       Date:  2019-12-24

7.  Accelerated habit formation following amphetamine exposure is reversed by D1, but enhanced by D2, receptor antagonists.

Authors:  Andrew J D Nelson; Simon Killcross
Journal:  Front Neurosci       Date:  2013-05-15       Impact factor: 4.677

Review 8.  Dopamine signaling in reward-related behaviors.

Authors:  Ja-Hyun Baik
Journal:  Front Neural Circuits       Date:  2013-10-11       Impact factor: 3.492

9.  To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity.

Authors:  Jeff A Beeler; Devry Mourra
Journal:  Front Integr Neurosci       Date:  2018-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.